Merrimack Pharmaceuticals

OverviewSuggest Edit

Merrimack is a fully integrated biopharmaceutical company that views cancer as a complex engineering challenge. Through systems biology, which brings together the fields of biology, computing and engineering, Merrimack aims to decrease uncertainty in drug development and clinical validation, and move discovery efforts beyond trial and error. Such an approach has the potential to make individualized treatment of patients a reality. Merrimack's first commercial product, ONIVYDETM (irinotecan liposome injection), was approved by the U.S. FDA and with four additional candidates in clinical studies, several in preclinical development and multiple biomarkers designed to support patient selection, the Company is building one of the most robust oncology pipelines in the industry.

TypePublic
Founded2000
HQCambridge, US
Websitemerrimack.com
Employee Ratings3

Latest Updates

Employees (est.) (Feb 2019)27(-62%)
Revenue (FY, 2016)$144.3 M(+62%)
Share Price (Feb 2020)$3.2 (+2%)

Key People/Management at Merrimack Pharmaceuticals

Richard Peters

Richard Peters

President and Chief Executive Officer

Merrimack Pharmaceuticals Office Locations

Merrimack Pharmaceuticals has an office in Cambridge
Cambridge, US (HQ)
1 Kendall Square
Show all (1)

Merrimack Pharmaceuticals Financials and Metrics

Merrimack Pharmaceuticals Revenue

Merrimack Pharmaceuticals's revenue was reported to be $144.27 m in FY, 2016 which is a 61.6% increase from the previous period.
USD

Net income (Q3, 2019)

(705.0k)

Market capitalization (21-Feb-2020)

43.0m

Closing stock price (21-Feb-2020)

3.2

Cash (30-Sept-2019)

20.9m
Merrimack Pharmaceuticals's current market capitalization is $43 m.
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

48.9m47.8m102.8m89.3m144.3m

Revenue growth, %

115%(13%)62%

Cost of goods sold

46.0k6.9m

Gross profit

89.2m137.4m
Quarterly
USDQ1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Revenue

11.3m12.1m11.3m14.7m18.5m6.9m13.0m27.8m28.0m14.8m36.6m16.4m21.3m33.7m28.1m

Cost of goods sold

711.0k1.9m1.0m

Gross profit

20.6m31.8m27.1m

Gross profit Margin, %

97%94%96%
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

37.7m65.1m35.7m185.6m21.5m93.4m20.1m

Accounts Receivable

9.3m5.9m3.3m6.5m17.5m100.0k

Prepaid Expenses

9.0m5.5m4.7m5.5m1.4m4.2m

Inventories

3.7m14.6m
Quarterly
USDQ1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Cash

30.6m32.0m27.9m28.4m30.9m105.5m66.9m77.8m100.3m28.8m33.7m56.4m48.2m21.5m36.5m17.2m135.5m107.2m34.3m22.5m49.8m36.5m36.9m20.9m

Accounts Receivable

6.0m6.9m6.1m9.8m14.5m8.8m12.2m6.6m2.6m4.2m1.8m2.1m15.6m19.3m22.2m43.0k43.0k190.0k

Prepaid Expenses

6.5m6.6m11.3m10.2m9.2m8.9m2.5m4.4m5.8m3.2m5.4m6.4m4.5m4.6m4.1m2.3m5.9m8.0m844.0k1.7m1.8m4.6m2.1m1.5m

Inventories

8.1m12.3m14.8m
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(91.3m)(130.7m)(83.6m)(147.8m)(153.5m)470.9m(40.5m)

Depreciation and Amortization

3.7m2.6m3.2m4.3m6.2m5.2m4.1m

Inventories

(3.7m)(9.7m)

Accounts Payable

7.0m13.3m(646.0k)13.6m(3.9m)(9.3m)(3.8m)
USDY, 2019

Financial Leverage

1.2 x
Show all financial metrics

Merrimack Pharmaceuticals Online and Social Media Presence

Embed Graph

Merrimack Pharmaceuticals News and Updates

Merrimack Pharmaceuticals Announces Changes to Board of Directors

Independent Directors Noah Levy of Newtyn and Eric Andersen of Western Standard to Be Added to Merrimack Board, Effective Immediately.read more

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Merrimack Pharmaceuticals, Inc. - MACK

NEW YORK, April 9, 2019 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Merrimack Pharmaceuticals, Inc. ("Merrimack" or the "Company") (NASDAQ: MACK). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext....

Merrimack Pharmaceuticals Blogs

Merrimack Pharmaceuticals Adopts Section 382 Net Operating Loss Rights Plan

Merrimack Pharmaceuticals Adopts Section 382 Net Operating Loss Rights Plan Content Import Tue, 12/03/2019 - 09:15 Merrimack Pharmaceuticals Adopts Section 382 Net Operating Loss Rights Plan December 3, 2019 This release is a backfill from a News Wire …

Merrimack Receives $5 Million Milestone Payment from Ipsen; Declares $6.7 Million Special Dividend

Merrimack Receives $5 Million Milestone Payment from Ipsen; Declares $6.7 Million Special Dividend Content Import Tue, 12/03/2019 - 08:45 Merrimack Receives $5 Million Milestone Payment from Ipsen; Declares $6.7 Million Special Dividend December 3, 2019 This …

Merrimack Pharmaceuticals Issues Letter to Shareholders

Company’s Board has Taken Crucial Actions to Maximize Shareholder Value and Preserve More than $500 Million in Potential Future Milestone Payments Merrimack’s Current Plan Follows Comprehensive Strategic Review Conducted with Leading Healthcare Financial Advisory Firm and Provides Best Pathway for

Merrimack Pharmaceuticals Reschedules 2019 Annual Meeting of Shareholders for October 17, 2019

Merrimack Pharmaceuticals Reschedules 2019 Annual Meeting of Shareholders for October 17, 2019 Content Import Fri, 08/16/2019 - 09:15 Merrimack Pharmaceuticals Reschedules 2019 Annual Meeting of Shareholders for October 17, 2019 August 16, 2019 This release i…

Merrimack Declares $20 Million Special Dividend

CAMBRIDGE, Mass. , July 25, 2019 /PRNewswire/ --  Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that its Board of Directors has authorized and declared a special cash dividend of $20 million on the Company's common stock. The special dividend is payable on September 5, 2019 to

Merrimack Pharmaceuticals Announces Completion of Strategic Review, Preservation of Ipsen Milestones and Special Cash Dividend

CAMBRIDGE, Mass. , May 30, 2019 /PRNewswire/ --   Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced the completion of its review of strategic alternatives, following which the Company's Board of Directors is implementing a series of measures designed to extend Merrimack's cash runway
Show more

Merrimack Pharmaceuticals Frequently Asked Questions

  • When was Merrimack Pharmaceuticals founded?

    Merrimack Pharmaceuticals was founded in 2000.

  • Who are Merrimack Pharmaceuticals key executives?

    Merrimack Pharmaceuticals's key executives are Richard Peters.

  • How many employees does Merrimack Pharmaceuticals have?

    Merrimack Pharmaceuticals has 27 employees.

  • Who are Merrimack Pharmaceuticals competitors?

    Competitors of Merrimack Pharmaceuticals include Del Mar Pharmaceuticals, Progenics Pharmaceuticals and Verastem.

  • Where is Merrimack Pharmaceuticals headquarters?

    Merrimack Pharmaceuticals headquarters is located at 1 Kendall Square, Cambridge.

  • Where are Merrimack Pharmaceuticals offices?

    Merrimack Pharmaceuticals has an office in Cambridge.

  • How many offices does Merrimack Pharmaceuticals have?

    Merrimack Pharmaceuticals has 1 office.